Side-by-side · Research reference

ProstamaxvsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/38 cited

BHuman-MechanisticAUTO-DRAFTED11/40 cited

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

Prostamax

Selank

Primary target

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

—

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

Prostamax

Selank

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

—

Human clinical dose

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

—

Evidence basis

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Human-mechanistic + Russian clinical trialsMedvedev 2007

Age groups studied

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

—

Duration

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

10–14 day cycles, repeated as needed

Standard dose

—

150–300 mcg / dose intranasalZaderej 2014

Frequency

—

2–3× per day during stress

Lower / starter dose

—

75 mcg / dose

Reconstitution

—

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

—

Morning + early afternoon preferred

Half-life

—

Short (minutes plasma); CNS effect lasts ~3 hr

04Side Effects & Safety

Parameter

Prostamax

Selank

Published adverse events

None reported in available literature

—

Genotoxicity signals

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

—

Metal ion interactions

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

—

Human safety data

Absent — no published Phase 1/2/3 trials

—

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

Prostamax

Selank

1. Route

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Reconstitution

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Frequency

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Monitoring

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Note

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

Avoid co-administration with strong sedatives or other anxiolytics initially.